The effects of nonspecific HIF1 alpha inhibitors on development of castrate resistance and metastases in prostate cancer
Weranja KB Ranasinghe, Shomik Sengupta, Scott Williams, Mike Chang, Arthur Shulkes, Damien M Bolton, Graham Baldwin, Oneel Patel
CANCER MEDICINE | WILEY-BLACKWELL | Published : 2014
Expression of hypoxia-inducible factor (HIF)1α increases the risk of castrate-resistant prostate cancer (CRPC) and metastases in patients on androgen deprivation therapy (ADT) for prostate cancer (PC). We aimed to investigate the effects of nonspecific HIF1α inhibitors (Digoxin, metformin, and angiotensin-2 receptor blockers) on development of CRPC and metastases while on ADT. A retrospective review of prospectively collected medical records was conducted of all men who had continuous ADT as first-line therapy for CRPC at the Austin Hospital from 1983 to 2011. Association between HIF1α inhibitor medications and time to develop CRPC was investigated using actuarial statistics. Ninety-eight pa..View full abstract
Awarded by National Health and Medical Research Council of Australia
This work was supported by National Health and Medical Research Council of Australia grant 1020983 (GSB) and by the Austin Medical Research Foundation.